Skip to content

Prepaid expenses at other companies

Eli Lilly logo
Eli LillyLLY
Immunovant, Inc. logo
Immunovant, Inc.IMVT

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%
EPS (diluted)-$0.98-55.6%

Balance sheet

See full
Cash & equivalents$298.5M+9.9%
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
Operating cash flow-$66.3M-73.8%
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.49B-45.9%
Enterprise value$1.29B-50.0%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×
Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:PrepaidExpenseCurrent.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's prepaid expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MoonLake Immunotherapeutics's prepaid expenses?
MoonLake Immunotherapeutics (MLTX) reported prepaid expenses of $32.96M in Q1 2026.
How has MoonLake Immunotherapeutics's prepaid expenses changed year-over-year?
MoonLake Immunotherapeutics's prepaid expenses increased by 42.4% year-over-year, from $23.15M to $32.96M.
What is the long-term trend for MoonLake Immunotherapeutics's prepaid expenses?
Over 5 years (2020 to 2025), MoonLake Immunotherapeutics's prepaid expenses has grown at a 140.7% compound annual growth rate (CAGR), from $283.06K to $22.86M.